The Incidence of Hepatocellular Carcinoma in Iran from 1996 to 2016: a Systematic Review and Meta-analysis
- 21 Downloads
Hepatocellular carcinoma or liver cancer (LC) is one of most important cancer around the world. There are several reports about LC incidence from various Iranian locations with conflicting results. The present study aimed to accomplish a systematic review to estimate the accurate incidence rate of LC among Iranian people.
This systematic review was performed based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist in 2018. A literature search was conducted using international databases (Medline/PubMed, Scopus, ScienceDirect, and Google Scholar) for English papers and national databases (Scientific Information Database, MagIran, IranMedex, and IranDoc) for Persian papers which estimated incidence rate of LC in any geographical area of Iran. The incidence rate of LC was calculated using random effect model.
Of 171 papers in the primary searches, 15 studies were included by advanced screening and refinement. The age-standardized rate (ASR) of LC was 1.66 (95% CI 1.49–1.83) for males and 1.25 (95% CI 1.12–1.38) for females.
The incidence rate of LC in Iran was lower in comparison to other countries. Afterwards, more studies are necessary to outline the accurate incidence rate and the trend of LC among Iranian population.
KeywordsIncidence Hepatocellular carcinoma Iran Systematic review Meta-analysis
This study was financially provided by Guilan University of Medical Sciences, Rasht, Iran.
Compliance with Ethical Standards
This study was conducted in compliance with the provisions of the Helsinki Declaration. The protocol was approved by the ethics committee of Guilan University of Medical Sciences.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 6.La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer. 2000;36(7):909–15.Google Scholar
- 7.Levi F, La Vecchia C, Lucchini F, Negri E. Worldwide trends in cancer mortality in the elderly, 1955-1992. Eur J Cancer. 1996;32A(4):652–72.Google Scholar
- 12.Joukar F, Mansour-Ghanaei F, Naghipour MR, Hassanipour S. Knowledge, distribution and risk factors of hepatitis B and C infection in High-risk Groups in Guilan Province, Iran. Hepat Mon. 2018;18(8):e65870.Google Scholar
- 16.Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prevent : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1994;3(3):209–12.Google Scholar
- 19.Saadat S, Yousefifard M, Asady H, Jafari AM, Fayaz M, Hosseini M. The most important causes of death in Iranian population; a retrospective cohort study. Emergency. 2015;3(1):16–21.Google Scholar
- 20.Azizi MH, Bahadori M, Azizi F. History of cancer in Iran. Arch Iran Med. 2013;16(10):613–22.Google Scholar
- 22.Mirzaei M, Ghoncheh M, Pournamdar Z, Soheilipour F, Salehiniya H. Incidence and trend of liver cancer in Iran. J Coll Physicians Surg Pak: JCPSP. 2016;26(4):306–9.Google Scholar
- 23.Nikbakht HA, Sahraian S, Ghaem H, Javadi A, Janfada M, Hassanipour S, et al. Trends in mortality rates for gastrointestinal cancers in Fars province, Iran (2005–2015). J Gastrointest Cancer. 2019:1-7. https://doi.org/10.1007/s12029-019-00204-1.
- 24.Deshpande S, van Asselt A, Tomini F, Armstrong N, Allen A, Noake C, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist. 2013.Google Scholar
- 25.Institute JB. The Joanna Briggs Institute Critical Appraisal tools for use in JBI systematic reviews checklist for analytical cross sectional studies. In: The Joanna Briggs institute. Australia: North Adelaide; 2017.Google Scholar
- 26.Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3–28.Google Scholar
- 27.Bagos PG, Nikolopoulos GK. Mixed-effects poisson regression models for meta-analysis of follow-up studies with constant or varying durations. Int J Biostat. 2009;5(1):1557–79.Google Scholar
- 28.Mehrabani D, Tabei SZ, Heydari ST, Shamsina SJ, Shokrpour N, Amini M, et al. Cancer occurrence in Fars province, southern Iran. Iran Red Crescent Me. 2008;10(4):314–22.Google Scholar
- 32.Babaei M, Jaafarzadeh H, Sadjadi AR, Samadi F, Yazdanbod A, Fallah M, et al. Cancer incidence and mortality in Ardabil: report of an ongoing population-based cancer registry in Iran, 2004-2006. Iran J Public Health. 2009;38(4):35–45.Google Scholar
- 33.Sadiadi A, Zahedi MJ, Moghadam SD, Nouraie M, Alimohammadian M, Ghorbani A, et al. The first population-based cancer survey in Kerman Province of Iran. Iran J Public Health. 2007;36(4):26–34.Google Scholar
- 34.Babai M, Mousavi S, Malek M, Danaie N, Jandaghi J, Tousi J, et al. Survey of cancer incidence during a 5-year (1998-2002) period in Semnan province. Koomesh. 2005;6(3):237–44.Google Scholar
- 35.Somi MH, Farhang S, Mirinezhad SK, Naghashi S, Seif-Farshad M, Golzari M. Cancer in East Azerbaijan, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev. 2008;9(2):327–30.Google Scholar
- 36.Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med. 2009;12(1):15–23.Google Scholar
- 37.Fateh M, Emamian MH. Cancer incidence and trend analysis in Shahroud, Iran, 2000 - 2010. Iran J Cancer Prev. 2013;6(2):85–94.Google Scholar
- 44.Hassanipour S, Mokhtari A, Fathalipour M, Salehiniya H. The Incidence of Lung Cancer in Iran: A Systematic Review and Meta-Analysis. World Cancer Research Journal. 2017;4(4):e980.Google Scholar
- 46.Rezaianzadeh A, Jalali M, Maghsoudi A, Mokhtari AM, Azgomi SH, Dehghani SL. The overall 5-year survival rate of breast cancer among Iranian women: a systematic review and meta-analysis of published studies. Breast Dis (Preprint). 2017;37(2):63–8 1–6.Google Scholar
- 47.Rezaianzadeh A, Mokhtari AM, Hassanipour S, Maghsoudi A, Dehghani SL, Nazarzadeh M, et al. The age-standardized incidence rate of ovarian cancer in Iranian women: a systematic review and meta-analysis. Middle East J Cancer. 2018;9(3):171–8.Google Scholar
- 48.Mokhtari AM, Riahi S, Fathalipour M, Delam H, Hashemnejad M, Hassanipour S. The age-standardized rate of female genital cancers in Iran: a systematic review and meta-analysis. Tums-Hayat. 2018;24(3):204–19.Google Scholar
- 49.Hassanipour S, Ghorbani M, Derakhshan M, Fouladseresht H, Mohseni S, Abdzadeh E, et al. The incidence of testicular cancer in Iran from 1996 to 2017: a systematic review and meta-analysis. Adv Human Biol. 2019a;9(1):16.Google Scholar
- 50.Hassanipour S, Namvar G, Fathalipour M, Ghorbani M, Abdzadeh E, Zafarshamspour S, et al. The incidence of brain tumours in Iran: a systematic review and meta-analysis. Adv Human Biol. 2019b;9(1):2.Google Scholar
- 51.Mohammadian M, Soroush A, Mohammadian-Hafshejani A, Towhidi F, Hadadian F, Salehiniya H. Incidence and mortality of liver cancer and their relationship with development in Asia. Asian Pac J Cancer Prev. 2016;17(4):2041–7.Google Scholar
- 54.Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J Res Med Sci. 2013;18(8):674–82.Google Scholar
- 55.Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon. 2008;8(4):281–94.Google Scholar
- 56.Aghamohamad A, Montazeri M, Akbari M. Prevalence of hepatitis B and hepatitis C in blood donors at Semnan province from 2008 to 2011. Koomesh. 2014;15(2):162–7.Google Scholar